Spyre Therapeutics, Inc. SYRE Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss?
- Spyre Therapeutics, Inc. (SYRE) reported debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss of $1.06M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss changed year-over-year?
- Spyre Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss increased by 556.5% year-over-year, from $161K to $1.06M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss has grown at a 50.5% compound annual growth rate (CAGR), from $34K to $116K.